REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 28th, 2010 • Puramed Bioscience Inc. • Pharmaceutical preparations • Illinois
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of May 24, 2010, by and between PURAMED BIOSCIENCE, INC., a Minnesota corporation, (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").
FORM OF WARRANT THIS COMMON STOCK PURCHASE WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE TRANSFERRED IN VIOLATION OF THE ACT, THE RULES AND REGULATIONS UNDER THE ACT, OR THE PROVISIONS OF THIS COMMON...Common Stock Purchase Warrant • May 28th, 2010 • Puramed Bioscience Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Lincoln Park Capital Fund, LLC (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 24, 2010 (the “Initial Exercise Date”) and on or prior to the close of business on the fifth anniversary of the date hereof (the “Termination Date”) but not thereafter, to subscribe for and purchase from PURAMED BIOSCIENCE, INC., a Minnesota corporation (the “Company”), up to 100,000 shares (the “Warrant Shares”) of Common Stock The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 8th, 2010 • Puramed Bioscience Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement ("Agreement"), dated February 2, 2010, is made by and between PURAMED BIOSCIENCE, INC., a Minnesota corporation ("Company"), and SOUTHRIDGE PARTNERS II, LP., a Delaware limited partnership (the "Investor").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 25th, 2012 • Puramed Bioscience Inc. • Pharmaceutical preparations • Utah
THIS SECURITIES PURCHASE AGREEMENT, dated as of September 7, 2012 (this “Agreement”), is entered into by and between PURAMED BIOSCIENCE, INC., a Minnesota corporation (the “Company”), and TONAQUINT, INC., a Utah corporation, its successors or assigns (the “Buyer”).
EQUITY CREDIT AGREEMENT BY AND BETWEEN PURAMED BIOSCIENCE, INC. AND SOUTHRIDGE PARTNERS II, LP Dated February 2, 2010Equity Credit Agreement • February 8th, 2010 • Puramed Bioscience Inc. • Pharmaceutical preparations • New York
THIS EQUITY CREDIT AGREEMENT entered into as of the 2th day of February, 2010 (this "AGREEMENT"), by and between SOUTHRIDGE PARTNERS II, LP, Delaware limited partnership ("INVESTOR"), and PURAMED BIOSCIENCE, INC., a corporation organized and existing under the laws of the State of Minnesota (the "COMPANY").
PURCHASE AGREEMENTPurchase Agreement • May 28th, 2010 • Puramed Bioscience Inc. • Pharmaceutical preparations • Illinois
PURCHASE AGREEMENT (the “Agreement”), dated as of May 24, 2010, by and between PURAMED BIOSCIENCE, INC., a Minnesota corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
MASTER EXCHANGE AGREEMENTMaster Exchange Agreement • April 30th, 2014 • Puramed Bioscience Inc. • Pharmaceutical preparations • New York
MASTER EXCHANGE AGREEMENT (this “Agreement”), dated as of April 24, 2014, by and among PuraMed BioScience, Inc., a corporation incorporated under the laws of the State of Minnesota, with its principal place of business located at 1326 Schofield Avenue, Schofield, Wisconsin 54476 (the “Company”) and Magna Group, LLC, a Texas limited liability company (the “Creditor”).
ContractWarrant Agreement • September 25th, 2012 • Puramed Bioscience Inc. • Pharmaceutical preparations • Utah
THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO PURAMED BIOSCIENCE, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.
WAIVER REGARDING WARRANTWaiver Regarding Warrant • May 12th, 2014 • Puramed Bioscience Inc. • Pharmaceutical preparations • Utah
This Waiver Regarding Warrant (this “Waiver”) is entered into as of May 8, 2014 (the “Effective Date”), by and between PURAMED BIOSCIENCE, INC., a Minnesota corporation (the “Company”), and TONAQUINT, INC., a Utah corporation, its successors or registered assigns (“Holder”).
ContractNote Agreement • July 16th, 2013 • Puramed Bioscience Inc. • Pharmaceutical preparations • Nevada
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. NEITHER THIS NOTE NOR ANY INTEREST OR PARTICIPATION THEREIN MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT OR APPLICABLE STATE SECURITIES LAWS; OR (II) IN THE ABSENCE OF AN OPINION OF COUNSEL, IN A FORM REASONABLY ACCEPTABLE TO THE ISSUER, THAT REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT OR; (III) UNLESS SOLD, TRANSFERRED OR ASSIGNED PURSUANT TO RULE 144 UNDER THE 1933 ACT.
Richard Berman Consulting AgreementConsulting Agreement • October 31st, 2012 • Puramed Bioscience Inc. • Pharmaceutical preparations • Wisconsin
THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into effective the date set forth below on the signature page by and between Richard Berman (the “Consultant”); whose principal place of business is 420 Lexington Avenue, Suite 350, New York, New York 10170 and PuraMed BioScience (the “Client”).
PuraMed BioScience, Inc. Convertible Promissory NoteConvertible Promissory Note • September 25th, 2012 • Puramed Bioscience Inc. • Pharmaceutical preparations • Utah
This Convertible Promissory Note (“Note”) is issued pursuant to that certain Securities Purchase Agreement dated September 7, 2012, as the same may be amended from time to time (the “Agreement”), by and between TONAQUINT, INC., a Utah corporation, or its registered assigns (the “Holder”), and PURAMED BIOSCIENCE, INC., a Minnesota corporation (the “Company”).
FIRST AMENDMENT TO CERTAIN AGREEMENTSLoan Agreement • July 16th, 2013 • Puramed Bioscience Inc. • Pharmaceutical preparations • Florida
This FIRST AMENDMENT TO CERTAIN AGREEMENTS (the “Amendment”) is dated effective as of the 27th day of June, 2013, by and between PURAMED BIOSCIENCE, INC., a Minnesota corporation (the “Company”), and TCA GLOBAL CREDIT MASTER FUND, LP, a Cayman Islands limited partnership (“TCA”).
